CMPS — COMPASS Pathways plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1816590 ·
Last close
$14.20
Market Cap
$1.97B
52W High
$15.40
52W Low
$10.59
ADV30
3,317,386
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -49,789,000 | -253,794,000 | 504,561,000 | 433,295,000 | 420,028,000 |
| Mar 2026 | 0 | — | -40,427,000 | 91,202,000 | 531,739,000 | 466,010,000 | 205,052,000 |
| Dec 2025 | 0 | — | -58,864,000 | -93,878,000 | 210,349,000 | 149,608,000 | 263,197,000 |
| Sep 2025 | 0 | — | -36,612,000 | -137,717,000 | 255,607,000 | 185,937,000 | 218,016,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-161,136,000
Investing CF
$0
Financing CF
$370,200,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.62
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-985,186,000
Inventory
—
Receivables
$15,155,000
ST Investments
—
EBIT TTM
$-391,641,000
Pretax Income TTM
$-396,831,000
Interest Exp TTM
$5,190,000
Analysts
16
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -175,290,000 | -287,862,000 | 210,349,000 | 263,197,000 | — | -157,240,000 |
| Dec 2024 | 0 | -157,108,000 | -155,122,000 | 213,666,000 | 58,971,000 | — | -119,186,000 |
| Dec 2023 | 0 | -124,044,000 | -118,464,000 | 275,987,000 | 50,243,000 | — | -97,376,000 |
| Dec 2022 | 0 | -95,979,000 | -91,505,000 | 197,294,000 | 16,014,000 | — | -105,451,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,977,000
NetIncome TTM
$-54,351,000
OpCashFlow TTM
$0
Assets (Latest)
$213,666,000
Forward EPS
$-1.43
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRGO | PERRIGO Co plc | $1.98B | $14.27 | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $1.95B | $32.64 | — |
| GHRS | GH Research PLC | $1.93B | $28.10 | — |
| NBTX | Nanobiotix S.A. | $2.01B | $39.66 | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.92B | $18.13 | — |
News headlines (Yahoo Finance, 1h cache)
CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics
2026-08-24 23:23 · Yahoo
COMPASS Pathways (CMPS) Q2 2026 Earnings Call Transcript
2026-08-12 17:43 · Yahoo
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances
2026-08-12 16:04 · Yahoo
Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
2026-08-06 11:00 · Yahoo
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
2026-08-06 10:30 · Yahoo
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
2026-07-27 14:38 · Yahoo
Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapy
2026-07-17 16:50 · Yahoo
Compass Pathways PLC (CMPS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and NDA ...
2026-08-05 19:01 · Yahoo
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-08-10 12:54 · Yahoo
COMPASS Pathways (CMPS) Could Be 45% Below Fair Value On VA Trial Collaboration
2026-08-07 19:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.